Eyconis Announces First Patients Dosed In Phase 1b/2a OVERTURE Trial Of EYC-0305 In Treatment-Naïve Wet AMD Patients, Using TransCon Technology Licensed From Ascendis Pharma

Benzinga Newsdesk www.benzinga.com Positive 50.7%

Neg 0% Neu 0% Pos 50.7%

Comments

No comments yet. Be the first!